Cellectis (CLLS) IPO Opens Up Flat

Today's IPO for Cellectis (NASDAQ: CLLS) opened for trading at $41.50 after pricing priced its 5,500,000 American Depositary Shares (ADSs) IPO at $41.50 per ADS. The IPO size was raised from 4,750,000.

In addition, Cellectis has granted the underwriters a 30-day option to purchase up to an additional 825,000 ADSs.

BofA Merrill Lynch, Jefferies and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Oppenheimer & Co. and Trout Capital are acting as co-managers for the offering.

Cellectis is a gene-editing company, which employs its core proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology.

Oil pr

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Encore Medical files for 3M share IPO on NYSE American at $5 per share
• MapLight Therapeutics raises $150M in private placement